1-12 of 12
Saengsuree Jootar, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Early Switching to Nilotinib As Second Line TKI in Patients with Chronic Myeloid Leukemia Who Were Intolerant to, Suboptimal to and Failed Imatinib: The Thai Multi-Centered Study

Pongtep Viboonjuntra, MD, PhD, Arnuparp Lekhakula, MD, M.S., Kanchana Chansung, MD, Chittima Sirijerachai, MD, Pimjai Niparuck, MD, Teeraya Pauvilai, MD, Tontanai Numbenjapon, MD, Udomsak Bunworasate, MD, Weerasak Nawarawong, MD, Adisak Tantiworawit, MD, Tawatchai Suwanban, MD, Saengsuree Jootar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4267.
https://doi.org/10.1182/blood-2018-99-117787
Published: 2018
Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Young Rok Do, PhDMD, Jae-Yong Kwak, MD PhD, Hawk Kim, MDPhD, Jeong-A Kim, MD PhD, Hyeoung-Joon Kim, MD PhD, Joon Seong Park, MD, Jooseop Chung, MD PhD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Udomsak Bunworasate, MD, Chul Won Choi, MD PhD, Narcisa Sonia Cornejo Comia, MD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Saengsuree Jootar, MD, Ary Harryanto Reksodiputro, MDPhD, Won-Sik Lee, MD, Yeung-Chul Mun, MD PhD, Jee Hyun Kong, MD, Priscilla B. Caguioa, MD, Jinny Park, MD PhD, Chul W. Jung, MD PhD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2018-99-110568
Published: 2018
Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Young Rok Do, MD PhD, Hawk Kim, MD PhD, Jae-Yong Kwak, Jeong-A Kim, Hyeoung-Joon Kim, Joon Seong Park, MD, Jooseop Chung, MD PhD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Udomsak Bunworasate, MD, Chul Won Choi, MD PhD, Narcisa Sonia Cornejo Comia, MD, Dae Young Zang, Sukjoong Oh, Saengsuree Jootar, MD, Ary Harryanto Reksodiputro, MDPhD, Won-Sik Lee, MD, Yeung-Chul Mun, MD PhD, Jee Hyun Kong, Priscilla B. Caguioa, MD, Jinny Park, MD PhD, Chul W. Jung, MD PhD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 317.
https://doi.org/10.1182/blood.V130.Suppl_1.317.317
Published: 2017
Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1816.
https://doi.org/10.1182/blood.V124.21.1816.1816
Published: 2014
Journal Articles

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD, PhD, Sang Kyun Sohn, MD, PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD, PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1499.
https://doi.org/10.1182/blood.V122.21.1499.1499
Published: 2013
Journal Articles

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, MD, Philipp D. le Coutre, MD, Josy Reiffers, Ricardo Pasquini, MD, Clarisse Lobo, MD, Richard E. Clark, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Ariful Haque, Richard A. Larson, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2010) 116 (21): 207.
https://doi.org/10.1182/blood.V116.21.207.207
Published: 2010
Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1115.
https://doi.org/10.1182/blood.V114.22.1115.1115
Published: 2009
Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD
Journal: Blood
Blood (2009) 114 (22): 2201.
https://doi.org/10.1182/blood.V114.22.2201.2201
Published: 2009
Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3286.
https://doi.org/10.1182/blood.V114.22.3286.3286
Published: 2009
Journal Articles

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Franck Nicolini, MD, Giuliana Alimena, MD, Haifa-Kathrin Al-Ali, MD, Andrey Zaritskey, Zhixiang Shen, MD, Saengsuree Jootar, MD, Graeme Smith, MD, Yanzhi Hsu, Maria Luisa Veronese, David A. Rizzieri
Journal: Blood
Blood (2007) 110 (11): 2960.
https://doi.org/10.1182/blood.V110.11.2960.2960
Published: 2007
Journal Articles

Reduced Intensity Hematopoietic Stem Cell Transplantation for Treatment of Class 3 Lucarelli Severe Thalassemia Patients.

Suradej Hongeng, MD, Samart Pakakasama, MD, Ampaiwan Chuansumrit, MD, Nongnuch Sirachainan, MD, Thanyachai Sura, MD, Suporn Chancharunee, MD, Artit Ungkanont, MD, Saengsuree Jootar, MD
Journal: Blood
Blood (2006) 108 (11): 5364.
https://doi.org/10.1182/blood.V108.11.5364.5364
Published: 2006
Journal Articles

Outcomes of Transplantation with Matched-Related Donor (MRD) and Alternative Donor (AD) Stem Cells in Children with Severe Thalassemia.

Suradej Hongeng, MD, Samart Pakakasama, MD, Ampaiwan Chuansumrit, MD, Nongnuch Sirachainan, MD, Watana Chaisiripoomkere, MD, Artit Ungkanont, MD, Saengsuree Jootar, MD
Journal: Blood
Blood (2004) 104 (11): 2160.
https://doi.org/10.1182/blood.V104.11.2160.2160
Published: 2004